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Introduction {#sec1}
============

Mesenchymal stem/stromal cells (MSCs) are attractive sources for a large number of cell-based therapies due to their self-renewal capacity and multi-lineage differentiation potential into bone, cartilage, and adipose tissues ([@bib4], [@bib1]). A major limitation of MSC-based therapy is that isolation of MSCs from bone marrow is an invasive process with potential adverse effects for the donor. Additionally, the proliferation and differentiation capacity of MSCs can vary between different donors with notable decreases as the donor patient age increases ([@bib13]). Thus, while MSCs isolated from bone marrow exhibit a promising potential for bone regeneration, there are shortcomings that may limit their overall effectiveness.

MSCs derived from human embryonic stem cells (hESCs) represent an attractive alternative particularly for bone regeneration because they have higher proliferation and osteogenic potential ([@bib2], [@bib12]). Several groups have developed a variety of methods to derive MSCs from ESCs that are biologically and phenotypically similar to bone marrow MSCs ([@bib6], [@bib11]). However, although there has been significant progress in developing protocols for hESC differentiation into MSCs, the differentiating or epigenetic programming of hESCs is a rather slow process that does not fulfill the requirements of tissue regeneration. Mesoderm derived from hESCs is a major source of multiple potent MSCs. Therefore, it is critical to identify potential inducing signals or epigenetic factors that might help to promote mesodermal differentiation of hESCs.

The highly conserved polycomb group (PcG) proteins are epigenetic modulators that carry out histone methylation to initiate and maintain the transcriptional repressive state of genes associated with differentiation to retain stem cell pluripotency in hESCs ([@bib5], [@bib10]). Mammalian PcG proteins are classified as two distinct complexes, the polycomb repressive complexes 1 and 2 (PRC1 and PRC2). While PRC1 recognizes the chromodomain of H3K27me3 to facilitate ubiquitination of H2AK119, PRC2 mediates the trimethylation of H3K27 at gene promoters. As a critical subunit of PRC2, EZH2 catalyzes the addition of methyl groups to H3K27 through the SET domain of its carboxy-terminal region and serves as a recruitment platform for DNA methyltransferases for gene silencing ([@bib7]). Here, we performed epigenome-wide comparisons of the transcriptome and histone modifications between hESCs and human ESC-derived MSCs using publicly available RNA sequencing (RNA-seq) and chromatin immunoprecipitation sequencing (ChIP-seq) data. This epigenome-wide map revealed that EZH2 was enriched in hESCs and was downregulated significantly in MSCs. We found that reducing H3K27me3 epigenetically promoted mesodermal differentiation of hESCs and generated more MSCs with multipotency.

Results {#sec2}
=======

EZH2 Expression Is Decreased Following hESC Differentiation into MSCs {#sec2.1}
---------------------------------------------------------------------

To generate the specific gene expression profile of MSCs following hESC differentiation, we used the RNA-seq data available from the NIH Roadmap Epigenomics project ([@bib16]). The gene expression profiles of hESCs and three hESC-derived lineages showed gene clusters that were either upregulated or downregulated in MSCs compared with hESCs ([Figure 1](#fig1){ref-type="fig"}A). Gene ontology (GO) analysis indicated that upregulated genes are highly enriched in categories related to skeletal system development, embryonic morphogenesis, and cell migration ([Figure 1](#fig1){ref-type="fig"}B), whereas downregulated genes are enriched in categories related to mitosis, organelle fission, DNA replication and repair, and chromosome function ([Figure 1](#fig1){ref-type="fig"}C). As the importance of epigenetic regulation in ESC differentiation is well established, we next examined the expression of epigenetic modulators ([Figure 1](#fig1){ref-type="fig"}D). Among these, *EZH2*, *JARID2*, and *DNMT3B* were the three most downregulated genes in MSCs compared with hESCs. Specifically, these epigenetic modulators are involved in repressive function, with EZH2 and JARID2 being associated with the trimethylation of H3K27 and DNMT3B with the methylation of DNA ([@bib9]) ([Figure 1](#fig1){ref-type="fig"}D). qRT-PCR confirmed that *JARID2*, *EZH2*, *SUV39H1*, and *KDM6A* were downregulated in hESC-derived MSCs ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). Since EZH2 and JARID2 are both components of PRC2, we investigated the gene expression of each individual PRC2 component. Comparative analysis of hESCs and MSCs revealed that all members of *PRC2*, *EZH2*, *SUZ12*, *EED*, *RbAp48*, and *JARID2* are reduced in MSCs compared with hESCs ([Figure 1](#fig1){ref-type="fig"}E). While *JARID2* exhibited the most significant decrease, its downregulation was observed in all three hESC-derived lineages ([Figure 1](#fig1){ref-type="fig"}E). Surprisingly, the downregulation of *EZH2* was specific to MSCs, with its upregulation observed in the other hESC-derived lineages ([Figure 1](#fig1){ref-type="fig"}E). Consistently, protein expression of EZH2 decreased dramatically after 3 days of hESC differentiation ([Figure 1](#fig1){ref-type="fig"}F).Figure 1Transcriptome Alterations in H1 hESC-Derived Lineages(A) Heatmaps showing the expression levels of coding genes in H1 hESCs and H1 hESC-derived cell lineages.(B and C) Gene ontology (GO) enrichment analysis for upregulated genes (B) and downregulated genes (C) in H1 hESC-derived MSCs. The GO terms include biological function. Bars represent −log~10~ of p values.(D) Fold changes of FPKM (fragments per kilobase of transcript per million mapped reads) value for genes encoding epigenetic modifiers in H1 hESC-derived lineages comparing with H1 hESCs. The y axis shows the log scale. Data are shown as mean ± SD from 2 replicates of RNA-seq data.(E) Average FPKM value of genes encoding core components of PRC2 complex in H1 hESCs and H1 hESC-derived lineages. Data are shown as mean ± SD from 2 replicates of RNA-seq data. ^∗^p \< 0.05; ^∗∗^p \< 0.01.(F) Western blot analysis of EZH2 level during differentiation of H1 hESCs to MSC.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Decreasing H3K27me3 on Specific Gene Clusters Associated with hESC Programming into MSCs {#sec2.2}
----------------------------------------------------------------------------------------

Both silencing H3K27me3 and activating H3K4me3 epigenetic marks, referred to as bivalent domains, occupy the EZH2-targeted genes in ESCs, working together to preserve ESC pluripotency and mediate rapid responses to differentiation signals ([@bib3]). Therefore, to further examine the epigenetic basis of hESC differentiation into MSCs, we profiled H3K27me3 and H3K4me3 marks in hESCs and MSCs with the use of ChIP-seq data ([@bib16]). Consequently, we identified 8,314 and 4,732 bivalent genes---those with binding sites for both H3K4me3 and H3K27me3---in H1 hESCs and MSCs, respectively ([Figure 2](#fig2){ref-type="fig"}A). Our data further indicated that, while there are 3,650 common bivalent genes in both H1 hESCs and MSCs, 4,664 bivalent genes disappear and 1,082 genes emerge solely in MSCs ([Figure 2](#fig2){ref-type="fig"}B, upper). We then selected developmental regulator genes that are bivalent in hESCs, but only have binding sites for H3K4me3---and are therefore transcriptionally active---in MSCs, identifying 3,982 genes ([Figure 2](#fig2){ref-type="fig"}B, lower). These genes are enriched for protein kinase activity, blood vessel development, and, notably, skeletal development ([Figure 2](#fig2){ref-type="fig"}C). Among them, we identified *BMP4*, *HOXC5*, and *TWIST1* ([Figure 2](#fig2){ref-type="fig"}D), genes that have been known to play a role in MSC behavior, thereby demonstrating that histone profiles can independently predict key hESC to MSC differentiation regulators.Figure 2Histone Marks in H1 hESC-Derived MSCs(A) The classification of RefSeq genes in terms of enrichment of H3K4me3 and H3K27me3 in H1 hESCs and H1 hESC-derived MSCs. Both and H3K4me3 co-occupy with H3K27me3.(B) Venn diagram showing bivalent domains change during hESC differentiation toward MSCs.(C) GO enrichment analysis of genes that were developmental regulators (bivalent in ESCs) and were activated in MSCs (lose H3K27me3). Bars represent −log~10~ of p values.(D) Representative peak tracks of H3K4me3 and H3K27me3 enrichment along *BMP4*, *HOXC5*, and *TWIST1* genes in H1 hESCs and H1 hESC-derived MSCs.(E) Profiles of H3K4me3 and H3K27me3 around TSS of genes that upregulated in MSCs. Red represents high intensity and white represents no signal. The profile plot shows the average reads at each relative position to TSS on the x axis with H3K4me3 and H3K27me3 coverage.(F) GO enrichment analysis of cluster 1 genes. Bars represent −log~10~ of p values.(G) GO enrichment analysis of cluster 2 genes. Bars represent −log~10~ of p values.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

We grouped the histone profiles of 3,087 RefSeq genes, whose expression levels were upregulated in MSCs. Clustering of the signal around the transcription start site (TSS) shows that H3K4me3 and H3K27me3 can be classified into two distinct clusters ([Figure 2](#fig2){ref-type="fig"}E). Cluster 1 heatmap showed high intensity and wide coverage (mean 3,200 bp) of H3K4me3 and H3K27me3 in H1 ESCs. Notably, H3K4me3 was also enriched around the TSS of MSCs, where H3K27me3 enrichment was absent. Cluster 2 showed no significant enrichment of either epigenetic signature within 5 kb of the TSS for both H1 ESCs and MSCs ([Figure 2](#fig2){ref-type="fig"}E). Interestingly, GO analysis using the functional annotation tool, DAVID Bioinformatics Resources 6.7, revealed that the co-presence of H3K4me3 and H3K27me3 at the TSS in hESCs, with little or no co-occupancy in MSCs, caused strong functional enrichment for genes involved in skeletal system development, embryonic development, and blood vessel development ([Figure 2](#fig2){ref-type="fig"}F). Genes enriched in cluster 2 were involved in signal transduction and cell proliferation (p \< 10^−8^) ([Figure 2](#fig2){ref-type="fig"}G). We also examined the H3K4me3 and H3K27me3 enrichment peaks around the TSS of genes that were downregulated in MSCs and found that they can be classified into three distinct clusters ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Cluster 1 contained a wide distribution of H3K4me3 in H1 ESCs that co-occupied with H3K27me3. Cluster 2 showed enrichment of H3K4me3 in both H1 ESCs and MSCs, while cluster 3 showed no significant enrichment of either histone mark in both H1 ESCs and MSCs ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Importantly, cluster 1 displayed a combination of decreased H3K4me3 enrichment, and increased H3K27me3 enrichment was observed in downregulated genes. Among these genes, GO analysis indicated that those that were the most downregulated in MSCs compared with hESCs are involved in cell signaling, synaptic transmission, cell-cycle processes, chromosomal organization, and organelle fission ([Figures S1](#mmc1){ref-type="supplementary-material"}D--S1F).

Inhibition of EZH2 Directs hESC Differentiation toward Mesoderm and Generates More MSCs {#sec2.3}
---------------------------------------------------------------------------------------

Next, we sought to understand the role of EZH2 in the differentiation of hESCs into MSCs. We treated hESCs with GSK126, a highly selective and potent inhibitor of EZH2. Western blot analysis showed that GSK126 potently inhibited EZH2\'s histone methyltransferase activity in hESCs, as demonstrated by an evident reduction in H3K27me3 ([Figure 3](#fig3){ref-type="fig"}A). Alkaline phosphatase (ALP) staining showed that GSK126 treatment dramatically inhibited ALP activities in both H1 and H9 hESCs ([Figure S2](#mmc1){ref-type="supplementary-material"}). We assessed the effects of EZH2 inactivation on the expression pattern of markers for the three germ layers. qRT-PCR revealed that multiple mesodermal markers, including *KDR*, *FOXF1*, *MSX1*, *T*, and *GATA4*, were significantly elevated upon GSK126 treatment ([Figures 3](#fig3){ref-type="fig"}B--3D). On the contrary, GSK126 significantly inhibited the expression of the ectodermal mark gene *TUBB3* and the endodermal gene *SOX17* and had a minimal effect on the expression of the ectodermal marker gene *PAX6* and endodermal marker gene *FOXA2*. Flow cytometry via fluorescence-activated cell sorting (FACS) staining confirmed that GSK126 treatment promoted KDR expression while it did not affect the expression of PAX6 and FOXA2 ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Interestingly, a similar pattern was seen in H9 hESCs, but with even more pronounced changes ([Figures 3](#fig3){ref-type="fig"}E--3G and [S2](#mmc1){ref-type="supplementary-material"}C). GO enrichment analysis of EZH2 ChIP-seq data in H1 hESCs revealed that EZH2 is enriched at the promoters of genes involved in developmental processes such as skeletal development and pattern specification ([Figure 3](#fig3){ref-type="fig"}H). To rule out the non-specific effect of GSK126, we knocked down *EZH2* in hESCs using small interfering RNA (siRNA) ([Figure 3](#fig3){ref-type="fig"}I). Consistently, siRNA-mediated *EZH2* depletion also led to enhanced expression of mesodermal markers ([Figure 3](#fig3){ref-type="fig"}J).Figure 3Effect of GSK126 Treatment on Differentiation of H1 hESCs and H9 hESCs(A) Western blot analysis of H3K27me3 level after 10 μM GSK126 treatment (upper panel); western blot of histone H3 serves as loading control (lower panel).(B--D) qRT-PCR analysis of mesodermal genes (*FOXF1*, *MSX1*, *T*, *KDR*, *GATA4*) (B), ectodermal genes (*TUBB3*, *PAX6*) (C), and endodermal genes (*SOX17*, *FOXA2*) (D) for H1 cells treated with DMSO or GSK126.(E--G) qRT-PCR analysis of mesodermal genes (*FOXF1*, *MSX1*, *T*, *KDR*, *GATA4*) (E), ectodermal genes (*TUBB3*, *PAX6*) (F), and endodermal genes (*SOX17*, *FOXA2*) (G) for H9 cells treated with DMSO or GSK126.(H) GO enrichment analysis of EZH2 enrichment within 1 kb of TSS for RefSeq genes in H1 hESCs.(I) Western blot analysis of EZH2 protein level after *EZH2* siRNA knockdown in H1 hESCs.(J) qRT-PCR analysis of mesodermal genes (*FOXF1*, *MSX1*, *T*, *KDR*, *GATA4*) after *EZH2* siRNA knockdown.Data are shown as mean ± SD; n = 3 independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001 by Student\'s t test. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Since the mesoderm is a major source of the mesenchymal precursors that enable the formation of skeletal and connective tissues ([@bib15]), we further explored lineage specification to MSCs by examining MSC surface markers. qRT-PCR analysis indicated that the mRNA levels of *CD73*, *CD146*, and *CD271* were significantly upregulated following 3 days of GSK126 treatment in H1 hESCs ([Figure 4](#fig4){ref-type="fig"}A) and H9 ESCs ([Figure S3](#mmc1){ref-type="supplementary-material"}A) in a dose-dependent manner. Such enhanced expression of MSC markers was further confirmed by flow-cytometry analysis ([Figures 4](#fig4){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}C).Figure 4Effect of GSK126 Treatment on Mesenchymal Lineage Commitment of H1 hESCs(A) qRT-PCR gene expression analysis of well-known MSC surface markers (*CD73*, *CD146*, and *CD271*).(B) Flow-cytometry analysis for CD73, CD146, and CD271 expression of cells treated with DMSO or GSK126.(C) ALP staining and quantitative ALP activity assay after 14 days of osteogenic induction (OI) for DMSO- or GSK126-treated cells. Scale bar, 300 μm.(D) ARS staining and quantification after 14 days of OI for DMSO- or GSK126-treated cells. Scale bar, 440 μm.(E) Alcian blue staining and quantification after 21 days of chondrogenic induction (CI) for DMSO- or GSK126-treated cells. Scale bar, 440 μm.(F and G) qRT-PCR gene expression analysis of osteogenic markers (*ALPL*, *RUNX2*, *IBSP*, and *BGLAP*) (F) and chondrogenic markers (*SOX9* and *COL2a1*) (G) after lineage-specific differentiation in H1 cells treated with or without GSK126.(H) Proportions of CD90^+^CD146^+^CD271^+^CD45^--^ H1-MSC-V and H1-MSC-126 are compared.(I) ALP staining and quantitative ALP activity assay of H1-MSC-V and H1-MSC-126 after 14 days of OI. Scale bar, 440 μm.(J) ARS staining and quantification of H1-MSC-V and H1-MSC-126 after 14 days of OI. Scale bar, 440 μm.(K) qRT-PCR gene expression analysis of osteogenic markers (*ALPL*, *RUNX2*, *IBSP*, and *BGLAP*) in H1-MSC-V and H1-MSC-126 after 14 days of OI.(L) Alcian blue staining and quantification (left) and qRT-PCR gene expression analysis of chondrogenic markers (*SOX9* and *COL2a1*) (right) of H1-MSC-V and H1-MSC-126 after 21 days of CI. Scale bar, 440 μm.(M) Oil red O staining and quantification (left) and qRT-PCR gene expression analysis of adipogenic markers (*PPARG* and *LPL*) (right) of H1-MSC-V and H1-MSC-126 after 21 days of adipogenic induction (AI). Scale bar, 440 μm.Data are shown as mean ± SD; n = 3 independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001 by Student\'s t test. See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

Since the inhibition of EZH2 by GSK126 appeared to generate more mesenchymal precursors from hESCs, we examined whether these differentiated cells from hESCs could be induced to differentiate into osteoblasts, chondrocytes, or adipocytes. We first treated H1 hESCs with either GSK126 or a vehicle control for 3 days, then transitioned them to a monolayer and cultured them in appropriate differentiation media. When these cells were induced to undergo osteogenic differentiation with osteogenic induction (OI) medium for 14 days, both ALP activity and the capacity to form mineralized nodules were significantly elevated in hESCs treated with GSK126 compared with the vehicle control ([Figures 4](#fig4){ref-type="fig"}C and 4D). Consistently, real-time RT-PCR showed elevated expression levels of osteogenic markers including *ALPL*, *RUNX2*, *IBSP*, and *BGLAP* ([Figure 4](#fig4){ref-type="fig"}F). Furthermore, we evaluated the chondrogenic capacity of differentiated hESCs with or without GSK126 treatment. Following treatment with chondrogenic induction (CI) medium for 21 days, GSK126-treated hESCs showed enhanced chondrogenic potential demonstrated by the presence of increased glycosaminoglycans and increased expression of chondrogenic markers *SOX9* and *COL2A1* ([Figure 4](#fig4){ref-type="fig"}E). Comparable results were also observed in GSK126-treated H9 hESCs compared with vehicle treatment ([Figures S3](#mmc1){ref-type="supplementary-material"}C--S3G). Interestingly, we were unable to induce adipogenic differentiation in these unsorted cells (data not shown).

Next, we sought to determine whether the increased osteogenic potentials following GSK126 treatment was due to an enhanced potency of individual mesenchymal precursors or a generation of more MSCs from hESCs. In general, MSCs positively express multiple cell-surface markers, including CD51, CD73, CD90, CD146, and CD271, and are negative for CD34 and CD45. To accomplish this, we treated H1 hESCs with either GSK126 or a vehicle control for 3 days. Subsequently, cells were trypsinized to generate a single-cell suspension for further differentiation for 5 days and then sorted by flow cytometry. Our preliminary analysis found that more than 95% of the cells were positive for CD51 and CD90 ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4C) and negative for CD34 ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4D). Therefore, we utilized the combination of markers CD73^+^CD146^+^CD271^+^CD45^--^ to isolate MSCs from differentiating hESCs excluding CD51, CD90, and CD34. FACS analysis indicated that, whereas 2.8% MSCs (H1-MSC-V) from differentiating hESCs without GSK126 treatment were isolated, GSK126 treatment generated an approximately 3-fold greater number of MSCs (H1-MSC-126) ([Figure 4](#fig4){ref-type="fig"}H). Since GSK126 treatment yielded more MSCs, it was important to demonstrate whether accelerating MSC fates by an epigenetic modifier did not impair the multiple potentials of MSCs from the aspect of regenerative medicine. The isolated H1-MSC-126 and H1-MSC-V cells by FACS were compared for their terminal differentiation capacity to develop into osteoblasts, chondrocytes, and adipocytes in the absence of GSK126. Importantly, ALP or Alizarin red staining revealed that H1-MSC-126 had same strong osteogenic potentials as H1-MSC-V ([Figures 4](#fig4){ref-type="fig"}I and 4J). Real-time RT-PCR showed that the expression of the osteogenic markers in H1-MSC-126, including *ALPL*, *RUNX2*, *IBSP*, and *BGLAP*, was induced at levels similar to those in H1-MSC-V upon OI treatment ([Figure 4](#fig4){ref-type="fig"}K). Following CI, both H1-MSC-126 and H1-MSC-V equivalently differentiated into chondrocytes ([Figure 4](#fig4){ref-type="fig"}L). Unlikely unsorted cells, both H1-MSC-126 and H1-MSC-V could differentiate into adipocytes as determined by oil red O staining. Real-time RT-PCR also confirmed that the adipogenic markers *PPARG* and *LPL* were similarly induced in both H1-MSC-126 and H1-MSC-V ([Figure 4](#fig4){ref-type="fig"}M). To further confirm our results, we also isolated MSCs from H9 hESCs treated with or without GSK126 using CD73^+^CD146^+^CD271^+^CD45^−^ markers. Consistently, we found that the inhibition of EZH2 by GSK126 also significantly increased the proportion of MSCs from H9 hESCs by 3-fold ([Figure S3](#mmc1){ref-type="supplementary-material"}H). MSCs derived from GSK126-treated H9 hESCs maintained osteogenic, chondrogenic, and adipogenic potentials *in vitro* ([Figures S3](#mmc1){ref-type="supplementary-material"}I--S3M).

Discussion {#sec3}
==========

In this study, we identified an epigenetic mechanism that facilitates controlled differentiation of pluripotent hESCs into mesodermal lineage. Through a comparative analysis of the transcriptome and epigenetic signatures between hESCs and MSCs, we found that PRC2 components were significantly downregulated in MSCs compared with hESCs. Further analysis revealed that among the most downregulated of PRC2 components in MSCs was EZH2. EZH2 serves as an essential force in the epigenetic landscape of embryonic development by mediating the silencing of a diverse group of developmental genes. Indeed, obliterating EZH2\'s function in replenishing H3K27me3 repressive signatures disturbed the equilibrium in the epigenetic landscape, leading to differentiation. Surprisingly, however, we observed a discerning rise in the expression of mesoderm and MSC markers and a concurrent decline in endoderm and ectoderm markers, indicating EZH2\'s distinguishing role in restricting commitment to mesodermal lineage. Importantly, we showed that the inhibition of EZH2 by the small-molecule inhibitor GSK126 potently produced higher volumes of mesodermal progenitors from hESCs, positioning EZH2 as a vital epigenetic modifier that regulates hESC differentiation into mesodermal lineage.

Because MSCs demonstrate high osteogenic potential with greater consistency and higher proliferation rate compared with MSCs from bone marrow, they may be better suited for regenerative medicine. Here, we identified the central epigenetic mechanism that directs hESCs to mesodermal linage as the incapacitation of EZH2 remodeled the epigenetic landscape in favor of MSC derivation. These results underscore a new duty of EZH2 in governing mesodermal commitment, beyond its established roles in ESC identity preservation and terminal differentiation. Mechanistically, when an inhibitor such as GSK126 binds to EZH2, its histone methyltransferase activity on H3K27 is disabled and repressive H3K27me3 marks are no longer sufficiently replenished, leading to disinhibition of target genes. As increasing the efficiency of MSC production is an important clinical goal, modulation of EZH2 will have profound implications for the future of regenerative medicine. While drugs targeting epigenetic modifiers are currently being investigated for therapeutic use in the treatment of cancer, autoimmune diseases, and neurological disorders, we provide strong evidence that epigenetic modifiers can also be utilized for enriched acquisition of MSCs with osteogenic potential from hESCs.

Experimental Procedures {#sec4}
=======================

Cell Culture and MSC Differentiation {#sec4.1}
------------------------------------

The protocol for the hESCs study was approved by UCLA Embryonic stem cells research oversight committee (IRB: 10-001711-CR-00001). H1 and H9 hESCs were obtained from the UCLA Broad Stem Cell Research Center. hESCs were cultured on a mitotically inactivated mouse embryonic feeder (MEF) layer, as previously described ([@bib14]), and cells were maintained for 35--45 passages. hESC colonies were detached by type IV collagenase (1 mg/mL), plated onto Matrigel-coated tissue culture dishes, and grown in mTeSR1 medium (catalog \#85850, STEMCELL Technologies; [@bib17], [@bib16]). Subsequently, GSK126 (10 μM; CAS \#1346574-57-9, Cayman Chemical) was added to the medium for 3 days every day. After 3 days of treatment, the derived cells were trypsinized to generate a single-cell suspension for further differentiation for 5 days and then sorted by flow cytometry. Osteogenic, chondrogenic, and adipogenic differentiation was induced as described previously ([@bib8], [@bib11]).

qRT-PCR {#sec4.2}
-------

Total RNA was isolated using the RNeasy Micro kit (Qiagen). First-strand cDNA was synthesized using random hexamers and reverse transcriptase according to the manufacturer\'s protocol (Invitrogen). RT-PCR was performed using the QuantiTect SYBR Green PCR kit (Qiagen) and the Icycler iQ Multi-color Real-time PCR Detection System (Bio-Rad). The primers for *GAPDH* are 5′-GGA GCG AGA TCC CTC CAA AAT-3′ (forward), 5′-GGC TGT TGT CAT ACT TCT CAT GG-3′ (reverse). The primers for *PAX6* are 5′-TGG GCA GGT ATT ACG AGA CTG-3′ (forward), 5′-ACT CCC GCT TAT ACT GGG CTA-3′ (reverse). The primers for *PDGFR-α* are 5′-TAT GTG CCA GAC CCA GAT GT-3′ (forward), 5′-GGA GTC TCG GGA TCA GTT GT-3′ (reverse). The primers for *CD73* are 5′-TTA CAC AGG CAA TCC ACC TTC-3′ (forward), 5′-TTA CAC AGG CAA TCC ACC TTC-3′ (reverse). The primers for *CD146* are 5′-CTG CTG AGT GAA CCA CAG GA-3′ (forward), 5′-CAC CTG GCC TGT CTC TTC TC-3′ (reverse).

Flow Cytometry and Fluorescence-Activated Cell Sorting {#sec4.3}
------------------------------------------------------

Cells were collected and washed twice with FACS buffer (PBS, 10 mM EDTA, and 2% fetal bovine serum) and suspended at a maximum concentration of 2 × 10^5^ cells per 100 μL. Cells were incubated with antibodies for 30 min on ice in the dark, washed, and suspended in PBS. Samples were analyzed on a BD LSR II analyzer or sorted on a BD FACSAria III. Cell gating was based on comparison with isotype-negative controls and single-stained controls. Cells were sorted into serum-free DMEM for gene expression analysis or into complete medium for cell culture. Antibodies used (all from BioLegend) included PE-CD34 (catalog \#343606), PerCP-Cy5.5-CD45 (\#368506), PE-CD51 (\#327910), APC-CD73 (\#344006), FITC-CD90 (\#328108), FITC-CD146 (\#361012), and PE-CD271 (\#345106).

External Data Source, ChIP-Seq Data Analysis, and RNA-Seq Data Analysis {#sec4.4}
-----------------------------------------------------------------------

Raw data for histone H3K4me3 and H3K27me3 ChIP-seq and raw data for RNA-seq of hESCs and hESC-derived lineages were downloaded from the NCBI epigenome roadmap (<http://www.ncbi.nlm.nih.gov/geo/roadmap/epigenomics/>). Data analysis was performed as described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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